- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04657302
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
January 18, 2024 updated by: Hoffmann-La Roche
A Phase I, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Glofitamab as Single Agent Administered After a Fixed, Single Dose Pretreatment of Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study will evaluate the pharmacokinetics, safety, tolerability, and efficacy of glofitamab as a single agent following a fixed single dose of obinutuzumab in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Beijing, China, 100191
- Peking University Third Hospital
-
Guangzhou City, China, 510060
- Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology
-
Harbin, China, 150081
- Harbin medical university cancer hospital
-
Nanjing, China, 210008
- Jiangsu Province Hospital
-
Tianjin, China, 300060
- Tianjin cancer hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically-confirmed DLBCL
- Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy (including at least one prior regimen containing anthracycline, and at least one containing an anti-CD20-directed therapy)
- Participants must have measurable disease: at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension; or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 1 or 1
- Adverse events from prior anti-cancer therapy must have resolved to Grade </=1
- Adequate liver, hematological, and renal function
- Negative serum pregnancy test within 7 days prior to study treatment in women of childbearing potential
- Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol, and agree to refrain from donating eggs during the treatment period and for at least 18 months after the final dose of obinutuzumab, 2 months after the final dose of glofitamab, and 3 months after the final dose of tocilizumab (if applicable)
- Men must agree to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol, and agree to refrain from donating sperm during the treatment period and for at least 3 months after the final dose of obinutuzumab, 4 months after the final dose of glofitamab, and 2 months after the final dose of tocilizumab (if applicable)
- Reside in the People's Republic of China
Exclusion Criteria:
- Richter's transformation
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection within 4 weeks prior to first study treatment
- Suspected or latent tuberculosis
- Positive for HIV, hepatitis C (HCV), or hepatitis B (HBV)
- Known or suspected chronic active Epstein-Barr virus infection
- Known or suspected history of hemaphagocytic lymphohistiocytosis (HLH)
- Prior treatment with systemic immunotherapeutic agents
- History of treatment-emergent immune-related adverse events associated with prior immunotherapeutic agents
- Documented refractoriness to an obinutuzumab monotherapy-containing regimen
- Treatment with standard radiotherapy, any chemotherapeutic agent, including CAR T therapy
- Prior solid organ or allogenic stem cell transplantation
- Autologous stem cell transplantation within 100 days prior to obinutuzumab infusion
- Active autoimmune disease requiring treatment
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Current or past history of CNS lymphoma
- Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders, and known autoimmune diseases
- Major surgery or significant traumatic injury < 28 days prior to obinutuzumab infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
- Another invasive malignancy in the last 2 years
- Significant cardiovascular disease
- Administration of a live, attenuated vaccine within 4 weeks before obinutizumab infusion, or anticipation that one will be required during the study
- Systemic immunosuppresive medications
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: R/R DLBCL
Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days).
|
Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants with Adverse Events (AEs)
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Serum Concentration of Glofitamab
Time Frame: At pre-defined intervals up to 3.5 years
|
At pre-defined intervals up to 3.5 years
|
Total Exposure (AUC) of Glofitamab
Time Frame: At pre-defined intervals up to 3.5 years
|
At pre-defined intervals up to 3.5 years
|
Maximum Serum Concentration (Cmax) of Glofitamab
Time Frame: At pre-defined intervals up to 3.5 years
|
At pre-defined intervals up to 3.5 years
|
Minimum Serum Concentration (Cmin) of Glofitamab
Time Frame: At pre-defined intervals up to 3.5 years
|
At pre-defined intervals up to 3.5 years
|
Clearance of Glofitamab
Time Frame: At pre-defined intervals up to 3.5 years
|
At pre-defined intervals up to 3.5 years
|
Volume of Distribution at Steady State (Vss) of Glofitamab
Time Frame: At pre-defined intervals up to 3.5 years
|
At pre-defined intervals up to 3.5 years
|
Half-life (T1/2) of Glofitamab
Time Frame: At pre-defined intervals up to 3.5 years
|
At pre-defined intervals up to 3.5 years
|
Complete Response Rate (CRR) as Assessed by an Independent Review Committee (IRC)
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Percentage of Participants with Anti-Drug Antibodies (ADA)
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Investigator-Assessed CRR
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Objective Response Rate (ORR) as Assessed by IRC
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
ORR as Assessed by Investigator
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Duration of Objective Response (DOR) as Assessed by IRC and Investigator
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Duration of Complete Response (CR) as Assessed by IRC and Investigator
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Progression-Free Survival (PFS) as Determined by IRC and Investigator
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Overall Survival (OS)
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Time to First Overall Response (TFOR) as Assessed by IRC and Investigator
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Time to First Complete Response (TFCR) as Assessed by IRC and Investigator
Time Frame: Up to 3.5 years
|
Up to 3.5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2021
Primary Completion (Actual)
October 25, 2022
Study Completion (Actual)
January 12, 2024
Study Registration Dates
First Submitted
December 1, 2020
First Submitted That Met QC Criteria
December 1, 2020
First Posted (Actual)
December 8, 2020
Study Record Updates
Last Update Posted (Estimated)
January 19, 2024
Last Update Submitted That Met QC Criteria
January 18, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YO42610
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org).
Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
Clinical Trials on Obinutuzumab
-
Institute of Hematology & Blood Diseases Hospital...RecruitingImmune Thrombocytopenia | TreatmentChina
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Michael ChoiPharmacyclics LLC.Withdrawn
-
Institute of Hematology & Blood Diseases HospitalRecruitingImmune Thrombocytopenia | TreatmentChina
-
Hoffmann-La RocheCompletedFollicular Lymphoma | Chronic Lymphocytic LeukemiaKorea, Republic of
-
French Innovative Leukemia OrganisationHoffmann-La RocheRecruiting
-
The First Affiliated Hospital with Nanjing Medical...RecruitingObinutuzumab | Rapid Infusion | Intravenous Infusion ReactionChina
-
Fondazione Italiana Linfomi - ETSRoche Pharma AGRecruiting
-
TG Therapeutics, Inc.CompletedChronic Lymphocytic LeukemiaUnited States
-
Paolo GhiaRecruitingChronic Lymphocytic LeukemiaItaly